Filling the need for trusted information on national health issues
Washington Post: Gilead delayed safer HIV drug to extend monopoly profits, advocates allege “…An HIV-prevention group called PrEP4All Collaboration filed a petition Wednesday with the U.S. Patent and Trademark Office contending Gilead knew its new, improved drug — approved in 2015 and now part of Gilead’s combination therapies Genvoya and…
New York Times: Who Owns HIV-Prevention Drugs? The Taxpayers, U.S. Says “It is very rare for the government to take on a drug maker over patents. But the medications made by Gilead are necessary to end the AIDS epidemic by 2030, which the Trump administration has set as a goal.…
Al Jazeera: Nigeria urged to ban chaining people with mental health issues (11/11). Borgen Magazine: Bill Gates on Decreasing Global Poverty (Dobson, 11/9). Deutsche Welle: Drug addiction in Russia: Draconian laws instead of help (Kauschanski, 11/11). Devex: A remote Congolese island offers a test case for improving the country’s health…
Axios: Federal lawsuit against Gilead puts patent rights on trial (Herman, 11/8). Financial Times: U.S. sues Gilead over HIV patent infringements (Mancini, 11/7). The Hill: Trump administration sues HIV prevention drug maker for patent infringement (Sullivan, 11/7). STAT: HHS sues Gilead for refusing to reach a licensing deal over patents…
New York Times: Trump Administration Sues Gilead, Maker of HIV-Prevention Drugs “The Trump administration on Wednesday sued Gilead Sciences, a pharmaceutical company that sells HIV-prevention drugs that can cost patients up to $20,000 a year [in the U.S.], accusing the company of earning billions from research funded by taxpayers without…
WHO Regional Office for Africa: Nine African countries agree to begin journey towards pooled procurement to increase their access to affordable life-saving vaccines “Nine middle-income countries in Africa have agreed to work towards pooled procurement mechanisms by first sharing vital information on their vaccine purchasing practices, including the prices they…
Borgen Magazine: The End Tuberculosis Now Act of 2019 (Gordon, 10/19). Los Angeles Times: Measles making a deadly comeback across Africa (Mahr, 10/20). New Dawn: Ellen Johnson Sirleaf’s vision for global health (10/17). New York Times: Venezuela’s Water System is Collapsing (Kurmanaev/Herrera, 10/19). NPR: Where You’re Born Even Within A…
CapX: Undermining private sector innovation puts lives at risk Jasson Urbach, director at the South Africa-based Free Market Foundation “…The world needs new approaches and solutions [to health care] — and innovation and intellectual property (IP) must be central parts of those solutions. The private sector has long been the…
The BMJ: Threat of compulsory licenses could increase access to essential medicines In this analysis, Gorik Ooms, professor of global health law and governance, and Johanna Hanefeld, associate professor of health policy and systems, both with the London School of Hygiene and Tropical Medicine, “argue that low- and middle-income countries…
STAT: Where was differential pricing at the WHO Fair Pricing Forum? Ed Schoonveld, managing principal and leader of the value and access practice at ZS Associates “…The complexity of the economics of drug development and lack of transparency about drug prices and R&D investments is infuriating many stakeholders. That sentiment…